Meet the expert sessions
The experts will meet with small groups of participants to discuss, face to face, the challenges and opportunities presented by working to promote lung health.
These sessions are free of charge for registered participants only. The number of persons attending each session should not exceed 30.
Registration for the 'Meet the expert' sessions is available on site, at the conference registration desk. Participation will be on a first-come, first-served basis.
SESSIONS
Sunday, 30 October 2011, 08:00-09:00
Caroline Bogren(Switzerland)
GDF procurement of tuberculosis drugs
Room: Artois
Fiona Godfrey (Luxembourg), Heather Selin (USA)
Next steps for NCDs
This session will look at recent developments in global policy on non-communicable diseases. In particular, an update will be given on the outcomes of the UN General Assembly Special Session on NCDs held on 19-20 September 2011. An update will be given on the final Outcomes document from the UNGASS. Prospects for and obstacles to the development of effective global and national policy and interventions on NCDs will be discussed.
Room: Faidherbe
Lucica Ditiu (Switzerland)
Partnership /PPM
Room: Matisse
Peter Donald (South Africa)
New drug doses and side-effects of drug-susceptible TB treatment regimens in children
Room: Van Gogh
Ria Grant (South Africa)
Community-based support for TB-HIV
Community based support for TB was introduced in the mid-1990s in the form of directly observed treatment (DOT) and a little later came community-based support for people living with HIV on ART was introduced. These are two diseases with differences and similarities, which are managed by two vertical programmes although they often affect one person. The presenter will relate the journey of TB/HIV Care Association, a non-governmental organisation, towards integrating TB and HIV in a community-based programme.
Room: Eurotop
Steve Lawn (UK)
ART scale-up: impact on TB control
Since existing interventions have failed to control the HIV-associated TB epidemic in sub-Saharan Africa, we will discuss the potential impact of scale-up of antiretroviral treatment (ART) on TB control and consider the major impact that a 'test and treat' ART strategy could have. Much remains to be learned, however. Despite the major benefits for treated individuals, the impact at a population level is much less clear and it has even been suggested that ART scale-up, done badly, could actually make things worse.
Room: Jeanne de Flandre 2
Hans L Rieder (Switzerland)
Cascade of regimens or tailoring a regimen to cover drug-resistant tuberculosis?
There is consensus that the primary choice of a first-line regimen for the treatment of tuberculosis should be standardised. Yet, there is considerable disagreement on how to approach treatment of multidrug-resistant tuberculosis. Should it be 1) a country-uniform standard regimen, 2) a regimen composed from drugs from various classes, or 3) a regimen based on drug susceptibility test results? This session will explore these options and present evidence why the most rational and pragmatic approach with a high likelihood of success is a cascade of standard regimens for any type of anti-tuberculosis treatment.
Room: Rotterdam